Genetic test may spare patients from unnecessary thyroid surgery

NCT ID NCT05025046

Completed Diagnosis Sponsor: Rigen Biotech Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study evaluates Thyroscan, a genomic test that analyzes genetic material from thyroid nodule samples, to see if it can accurately distinguish benign from malignant nodules. The trial involves 250 adults with suspicious thyroid nodules who are scheduled for surgery or have stable benign cytology. The goal is to measure the test's sensitivity, specificity, and overall diagnostic accuracy compared to standard cytopathology.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thyroscan, a genomic classifier test that analyzes genetic material from a thyroid nodule sample to help determine if it is benign or malignant.
What this could lead to: If accurate, Thyroscan could help many people with suspicious thyroid nodules avoid unnecessary surgery by reliably identifying benign ones.
What could go wrong: The test is still being studied and may not be accurate enough to replace current methods. Its performance in real-world settings is not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer Thyroid Neoplasms Thyroid Nodule

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER THYROID NODULE

Contacts and locations

Locations

Shanghai Jiaotong University School of Medicine

Shanghai, 200000, China
The First Peple's Hospital of Changzhou

Changzhou, Jiangsu, 213000, China
Tianjin Medical University Center Hospital

Tianjin, 300000, China
Zhejiang Provincial People's Hospital

Hangzhou, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.